NPA Addresses Rising State Restrictions and Regulatory Clarity

The Natural Products Association (NPA) is tackling significant challenges facing the dietary supplement industry, as outlined by its president and CEO, Daniel Fabricant, PhD. The discussion highlighted growing state-level sales restrictions that have expanded dramatically from Massachusetts, where such measures originated eight years ago, to now include twenty states. The latest proposal comes from Alaska, where lawmakers aim to prohibit the sale of weight loss and muscle-building products to minors.

In response to this increasing trend of restrictive legislation, Rep. Nick Langworthy (R-N.Y.) has introduced the Dietary Supplement Regulatory Uniformity Act. This initiative seeks to reinforce federal oversight of dietary supplements and prevent states from imposing additional regulatory requirements. Dr. Fabricant emphasized the need for a consistent regulatory framework, stating, “Other FDA-regulated industries enjoy federal preemption. We think it makes a heck of a lot of sense here. Why are we coming up with a patch quilt of regulations when we have an authority, a very competent one in the FDA? Let’s let them do their job.”

The urgency for congressional action is palpable, with Dr. Fabricant warning that failure to act could result in even more stringent state regulations. He underscored the importance of industry stakeholders engaging with legislators and securing co-sponsors to demonstrate the viability of federal oversight.

Addressing Regulatory Confusion

Dr. Fabricant also tackled the confusion surrounding emerging ingredients, particularly peptides and precision fermentation. He stressed the necessity for the FDA to provide clarity on definitional boundaries to establish a clear regulatory pathway for these products. While he acknowledged that updating the definition of dietary supplements is not immediately required, he noted that greater clarity is essential for issues such as drug preclusion and state preemption.

Concerns regarding impending self-affirmed Generally Recognized As Safe (GRAS) rules were also addressed. Dr. Fabricant urged industry members to refrain from panic while acknowledging that the FDA is currently deliberating these important issues.

Looking towards the future, the NPA is preparing for its annual federal government advocacy fly-in day next month. During this event, the association plans to engage with lawmakers on Capitol Hill to discuss state bills, drug preclusion, self-GRAS, and other pressing matters. Dr. Fabricant remarked, “There are over 4,600 associations in D.C., many of them are having their fly-ins as we speak. We’ve got to fight for oxygen on this issue, so it’s really important that they see myself, they see Kyle [Turk], they see Josh [Long], they see the NPA team every day. They want to hear from the constituents.”

The NPA’s proactive approach highlights the ongoing challenges the dietary supplement industry faces as it navigates an evolving regulatory landscape.